Oncocross Co., Ltd. (KOSDAQ:382150)

Market Cap	114.58B
Revenue (ttm)	884.68M +103.0%
Net Income	-8.33B
EPS	-716.67
Shares Out	12.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,104
Average Volume	184,291
Open	9,460.00
Previous Close	9,460.00
Day's Range	9,220.00 - 9,550.00
52-Week Range	7,490.00 - 16,700.00
Beta	n/a
RSI	48.92
Earnings Date	Mar 20, 2026

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 382150

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.